F S&P 500
5,481.00 +4.25 (+0.08%) F Dow Jones
39,161.00 +14.00 (+0.04%) F Nasdaq
19,805.25 +42.00 (+0.21%) E-mini Russell 2000 Index Futur
2,043.70 +4.00 (+0.20%) Petróleo
82.34 +0.17 (+0.21%) Oro
2,378.60 +9.60 (+0.41%)
Recursion Pharmaceuticals, Inc. (RXRX)
Fuera de horario:
Recursion Pharmaceuticals, Inc.
41 South Rio Grande Street
Salt Lake City, UT 84101
United States
385 269 0203
https://www.recursion.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 500
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Christopher C. Gibson Ph.D. | Co-Founder, CEO & Director | 806.72k | 2.18M | 1983 |
| Ms. Tina Marriott Larson | COO & President | 702.24k | 397.61k | 1975 |
| Dr. Blake C. Borgeson Ph.D. | Co-Founder & Director | 40k | N/D | 1982 |
| Dr. Michael Secora Ph.D. | Chief Financial Officer | 629.78k | 3.62M | 1983 |
| Dr. David J. Mauro M.D., Ph.D. | Chief Medical Officer | 674.74k | N/D | 1965 |
| Kevin Leggat | Vice President of Finance & Accounting | N/D | N/D | N/D |
| Mr. Benjamin Mabey M.S. | Chief Technology Officer | N/D | N/D | 1983 |
| Mr. Jared Allenbach | Senior Director of Investor Relations | N/D | N/D | N/D |
| Mr. Nathan Hatfield | Chief Legal Officer & General Counsel | N/D | N/D | N/D |
| Mr. Ryan Kelly | Chief Communications Officer | N/D | N/D | N/D |
Descripción
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.
Gestión corporativa
La calificación ISS Governance QuickScore de Recursion Pharmaceuticals, Inc. a partir del 1 de junio de 2024 es 8. Las puntuaciones principales son Auditoría: 3; Junta: 6; Derechos del accionista: 10; Compensación: 9.
